High doses of vitamin E in the treatment of disorders of the central nervous system in the aged

Govind T. Vatassery, Timothy Bauer, Maurice W Dysken

Research output: Contribution to journalReview article

71 Citations (Scopus)

Abstract

Oxidative stress is a putative factor in the pathogenesis of many human disorders of the central nervous system. Therefore, antioxidants such as vitamin E have become attractive as therapeutic agents in the treatment of several diseases. In addition, vitamin E seems to play a specific role in the nervous system. As a result, vitamin E has been used in pharmacologic doses in the treatment of disorders such as Parkinson disease. Alzheimer disease, and tardive dyskinesia. One investigation showed that the use of 2000 IU all- rac-α-tocopheryl acetate is beneficial in the treatment of Alzheimer disease. Similar doses of vitamin E, however, were not beneficial for delaying the progression of Parkinson disease. In other studies, dosages ≥400 IU vitamin E/d were found to be beneficial in the treatment of tardive dyskinesia, although this finding was not confirmed in a larger cooperative study conducted by the Veterans Administration. Even though the efficacy of vitamin E in the management of cardiovascular disease has been shown, the potential role of vitamin E in the treatment of cerebrovascular disease remains essentially unknown. The experience from 2 large clinical trials involving the oral intake of 2000 IU vitamin E/d suggests that vitamin E is relatively safe at this dosage for periods <2 y. However, the safety and efficacy of supplemental vitamin E over periods of many years in the prevention of neurologic diseases has not been adequately explored.

Original languageEnglish (US)
Pages (from-to)793-801
Number of pages9
JournalAmerican Journal of Clinical Nutrition
Volume70
Issue number5
StatePublished - Nov 1 1999

Fingerprint

Central Nervous System Diseases
Vitamin E
Parkinson Disease
Alzheimer Disease
Cerebrovascular Disorders
United States Department of Veterans Affairs
alpha-Tocopherol
Nervous System Diseases
Nervous System
Oxidative Stress
Cardiovascular Diseases
Antioxidants
Clinical Trials
Safety

Keywords

  • Aged
  • Alzheimer disease
  • Antioxidants
  • Cardiovascular disease
  • Central nervous system
  • Elderly
  • Megadose
  • Parkinson disease
  • Tardive dyskinesia
  • Therapeutic agent
  • Vitamin E
  • α-tocopherol

Cite this

High doses of vitamin E in the treatment of disorders of the central nervous system in the aged. / Vatassery, Govind T.; Bauer, Timothy; Dysken, Maurice W.

In: American Journal of Clinical Nutrition, Vol. 70, No. 5, 01.11.1999, p. 793-801.

Research output: Contribution to journalReview article

Vatassery, Govind T. ; Bauer, Timothy ; Dysken, Maurice W. / High doses of vitamin E in the treatment of disorders of the central nervous system in the aged. In: American Journal of Clinical Nutrition. 1999 ; Vol. 70, No. 5. pp. 793-801.
@article{ade2d6e0246245d39df9332e2a271e2f,
title = "High doses of vitamin E in the treatment of disorders of the central nervous system in the aged",
abstract = "Oxidative stress is a putative factor in the pathogenesis of many human disorders of the central nervous system. Therefore, antioxidants such as vitamin E have become attractive as therapeutic agents in the treatment of several diseases. In addition, vitamin E seems to play a specific role in the nervous system. As a result, vitamin E has been used in pharmacologic doses in the treatment of disorders such as Parkinson disease. Alzheimer disease, and tardive dyskinesia. One investigation showed that the use of 2000 IU all- rac-α-tocopheryl acetate is beneficial in the treatment of Alzheimer disease. Similar doses of vitamin E, however, were not beneficial for delaying the progression of Parkinson disease. In other studies, dosages ≥400 IU vitamin E/d were found to be beneficial in the treatment of tardive dyskinesia, although this finding was not confirmed in a larger cooperative study conducted by the Veterans Administration. Even though the efficacy of vitamin E in the management of cardiovascular disease has been shown, the potential role of vitamin E in the treatment of cerebrovascular disease remains essentially unknown. The experience from 2 large clinical trials involving the oral intake of 2000 IU vitamin E/d suggests that vitamin E is relatively safe at this dosage for periods <2 y. However, the safety and efficacy of supplemental vitamin E over periods of many years in the prevention of neurologic diseases has not been adequately explored.",
keywords = "Aged, Alzheimer disease, Antioxidants, Cardiovascular disease, Central nervous system, Elderly, Megadose, Parkinson disease, Tardive dyskinesia, Therapeutic agent, Vitamin E, α-tocopherol",
author = "Vatassery, {Govind T.} and Timothy Bauer and Dysken, {Maurice W}",
year = "1999",
month = "11",
day = "1",
language = "English (US)",
volume = "70",
pages = "793--801",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "5",

}

TY - JOUR

T1 - High doses of vitamin E in the treatment of disorders of the central nervous system in the aged

AU - Vatassery, Govind T.

AU - Bauer, Timothy

AU - Dysken, Maurice W

PY - 1999/11/1

Y1 - 1999/11/1

N2 - Oxidative stress is a putative factor in the pathogenesis of many human disorders of the central nervous system. Therefore, antioxidants such as vitamin E have become attractive as therapeutic agents in the treatment of several diseases. In addition, vitamin E seems to play a specific role in the nervous system. As a result, vitamin E has been used in pharmacologic doses in the treatment of disorders such as Parkinson disease. Alzheimer disease, and tardive dyskinesia. One investigation showed that the use of 2000 IU all- rac-α-tocopheryl acetate is beneficial in the treatment of Alzheimer disease. Similar doses of vitamin E, however, were not beneficial for delaying the progression of Parkinson disease. In other studies, dosages ≥400 IU vitamin E/d were found to be beneficial in the treatment of tardive dyskinesia, although this finding was not confirmed in a larger cooperative study conducted by the Veterans Administration. Even though the efficacy of vitamin E in the management of cardiovascular disease has been shown, the potential role of vitamin E in the treatment of cerebrovascular disease remains essentially unknown. The experience from 2 large clinical trials involving the oral intake of 2000 IU vitamin E/d suggests that vitamin E is relatively safe at this dosage for periods <2 y. However, the safety and efficacy of supplemental vitamin E over periods of many years in the prevention of neurologic diseases has not been adequately explored.

AB - Oxidative stress is a putative factor in the pathogenesis of many human disorders of the central nervous system. Therefore, antioxidants such as vitamin E have become attractive as therapeutic agents in the treatment of several diseases. In addition, vitamin E seems to play a specific role in the nervous system. As a result, vitamin E has been used in pharmacologic doses in the treatment of disorders such as Parkinson disease. Alzheimer disease, and tardive dyskinesia. One investigation showed that the use of 2000 IU all- rac-α-tocopheryl acetate is beneficial in the treatment of Alzheimer disease. Similar doses of vitamin E, however, were not beneficial for delaying the progression of Parkinson disease. In other studies, dosages ≥400 IU vitamin E/d were found to be beneficial in the treatment of tardive dyskinesia, although this finding was not confirmed in a larger cooperative study conducted by the Veterans Administration. Even though the efficacy of vitamin E in the management of cardiovascular disease has been shown, the potential role of vitamin E in the treatment of cerebrovascular disease remains essentially unknown. The experience from 2 large clinical trials involving the oral intake of 2000 IU vitamin E/d suggests that vitamin E is relatively safe at this dosage for periods <2 y. However, the safety and efficacy of supplemental vitamin E over periods of many years in the prevention of neurologic diseases has not been adequately explored.

KW - Aged

KW - Alzheimer disease

KW - Antioxidants

KW - Cardiovascular disease

KW - Central nervous system

KW - Elderly

KW - Megadose

KW - Parkinson disease

KW - Tardive dyskinesia

KW - Therapeutic agent

KW - Vitamin E

KW - α-tocopherol

UR - http://www.scopus.com/inward/record.url?scp=0032744787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032744787&partnerID=8YFLogxK

M3 - Review article

VL - 70

SP - 793

EP - 801

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - 5

ER -